Plasma endogenous metabolome as superior biomarkers for adverse effects compared to drug and its metabolites
Our study demonstrates that pre-chemotherapy endogenous plasma metabolome serve as superior biomarkers for predicting CRAEs, outperforming drug exposure levels. However, the limited sample size may impact the generalizability of these findings, and validation in larger patient cohorts is warranted.<b>Trial Registration:</b> NCT03030508 (registered at www.clinicaltrials.gov).
Authors
- W. Chen
- Shouhong Gao
- Mengxuan Yang
- Lifeng Huang
- Xia Tao
- Xingyun Hou
- Tao Yan
- Xuan Liu
- Zhipeng Wang
- Yi Deng
- Mingming Li
- Shi Qiu
- Jiani Chen
Institutions
- Fudan University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Integrated Chinese Medicine (China) (HK)
- Shanghai University of Medicine and Health Sciences (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1080/14796694.2025.2609305
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00